Arcitumomab
Trade name: cea-scan
mAbapprovedADC
Approved
Jun 28, 1996
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
1990s
- Jun 28, 1996
Earliest FDA Approval
Indications
Approved for
Mechanism of action
CEACAM5 binding agent
- Unspecified targetOTHER
Diagnostic agent
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, passive
CEACAM5 immunity, passive
Approval history
- approvedJun 28, 1996
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Availability
- Discontinued
- Multi-specific
- No
- Payload
- 131-iodine
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109296 ↗
- ChEMBLCHEMBL2108253 ↗
- ChEMBLCHEMBL1743090 ↗
Also known as
- arcitumomab
- arcitumomab
- arcitumomab
- arcitumomab
- arcitumomab
- arcitumomab
- arcitumomab
- arcitumomab 99tc
- arcitumomab technetium-99m
- arcitumomab technetium-99m
- cea-scan
- cea-scan
- cea-scan
- cea-scan
- immu-4
- immu-4fab'-tc99m
- pintumomab 99tc
- technetium-99m arcitumomab
- technetium-99m arcitumomab
- technetium (99mtc) arcitumomab
- technetium (99mtc) arcitumomab
- technetium (99mtc) arcitumomab
- technetium tc 99m arcitumomab
- technetium tc 99m arcitumomab
- technetium tc 99m arcitumomab
- technetium tc 99m arcitumomab
- technetium tc-99m arcitumomab
- technetium tc-99m arcitumomab